Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

OMEGA THERAPEUTICS, INC.

(OMGA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Omega Therapeutics, Inc. Announces Strategic Research Collaboration with Stanford University School of Medicine

10/14/2021 | 07:00am EST

Omega Therapeutics, Inc. ("Omega") announced a strategic research collaboration with researchers at the Stanford University School of Medicine to explore the therapeutic potential of Omega Epigenomic Controllers (OECs) to control ocular disease genes associated with inflammation or regeneration of ocular tissues. Under the terms of the collaboration, Omega and members of the Ophthalmology Department of Stanford University School of Medicine will use the OMEGA Epigenomic Programming platform to discover and research novel ocular targets for potential future OEC development candidates. Albert Wu, M.D., Ph.D., FACS, Associate Professor of Ophthalmology, will serve as principal investigator. Other contributors will include Jeffrey Goldberg, M.D., Ph.D., Professor and Chair of Ophthalmology, and Michael Kapiloff, M.D., Ph.D., Associate Professor (Research) of Ophthalmology.


ę S&P Capital IQ 2021
All news about OMEGA THERAPEUTICS, INC.
11/18Omega Therapeutics to Participate in the Piper Sandler 33rd Annual Virtual Healthcare C..
PR
11/10Omega Therapeutics Narrows Loss in Q3
MT
11/10Omega Therapeutics Reports Third Quarter 2021 Financial Results and Outlines Key Corpor..
PU
11/10OMEGA THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition a..
AQ
11/10Omega Therapeutics Reports Third Quarter 2021 Financial Results and Outlines Key Corpor..
PR
11/09Omega Therapeutics to Present at the Jefferies London Healthcare Conference
PR
11/08OMEGA THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Creation of a Direc..
AQ
10/14OMEGA THERAPEUTICS : Working With Stanford University to Explore Use of Omega Epigenomic C..
MT
10/14OMEGA THERAPEUTICS : Announces Strategic Research Collaboration with Stanford University S..
PR
10/14Omega Therapeutics, Inc. Announces Strategic Research Collaboration with Stanford Unive..
CI
More news
Analyst Recommendations on OMEGA THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2021 - - -
Net income 2021 -71,6 M - -
Net cash 2021 209 M - -
P/E ratio 2021 -6,60x
Yield 2021 -
Capitalization 847 M 847 M -
EV / Sales 2021 -
EV / Sales 2022 -
Nbr of Employees -
Free-Float 96,3%
Chart OMEGA THERAPEUTICS, INC.
Duration : Period :
Omega Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends OMEGA THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 17,73 $
Average target price 29,50 $
Spread / Average Target 66,4%
EPS Revisions
Managers and Directors
Mahesh Karande President, Chief Executive Officer & Director
Roger A. Sawhney Chief Financial Officer
Noubar B. Afeyan Chairman
Thomas McCauley Chief Scientific Officer
Mary T. Szela Director
Sector and Competitors
1st jan.Capi. (M$)
OMEGA THERAPEUTICS, INC.0.00%847
MODERNA, INC.197.32%125 937
LONZA GROUP AG28.34%58 955
IQVIA HOLDINGS INC.44.70%49 527
SEAGEN INC.-9.64%28 937
CELLTRION, INC.-40.67%24 625